| Literature DB >> 23271737 |
Jeff A O'Meara1, Christopher T Lemke, Cédrickx Godbout, George Kukolj, Lisette Lagacé, Benoît Moreau, Diane Thibeault, Peter W White, Montse Llinàs-Brunet.
Abstract
Although optimizing the resistance profile of an inhibitor can be challenging, it is potentially important for improving the long term effectiveness of antiviral therapy. This work describes our rational approach toward the identification of a macrocyclic acylsulfonamide that is a potent inhibitor of the NS3-NS4A proteases of all hepatitis C virus genotypes and of a panel of genotype 1-resistant variants. The enhanced potency of this compound versus variants D168V and R155K facilitated x-ray determination of the inhibitor-variant complexes. In turn, these structural studies revealed a complex molecular basis of resistance and rationalized how such compounds are able to circumvent these mechanisms.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23271737 PMCID: PMC3581377 DOI: 10.1074/jbc.M112.439455
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157